Tupy (TUPY3) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
15 May, 2026Executive summary
Net revenue reached BRL 2.3 billion, down 7% year-over-year, mainly due to lower sales volumes and currency appreciation, partially offset by new contracts and growth in Manufacturing Contracts and Energy & Decarbonization units.
Adjusted EBITDA fell 60% to BRL 99 million (4.3% margin), with net loss of BRL 94 million, impacted by lower volumes and adverse FX, but partially offset by efficiency gains and a better product mix.
Record operating cash flow for a first quarter at BRL 198 million, driven by working capital improvements and inventory reductions.
New contracts contributed BRL 100 million in revenue, with expectations to exceed BRL 600 million in 2026.
Market recovery visible in commercial vehicles in the U.S. and Europe, with order books exceeding budget and OEMs revising forecasts upward.
Financial highlights
Gross margin at 10.1%, pressured by lower production volumes and cost inflation.
Financial expenses up 10% year-over-year; financial revenues up 38%.
Net debt at BRL 2.1 billion, down 18% year-over-year; leverage at 4.02x adjusted EBITDA.
Cash and cash equivalents at quarter-end: BRL 1.82 billion.
Investments in PP&E and intangibles totaled BRL 64 million, up 3% year-over-year.
Outlook and guidance
Q2 expected to improve sequentially, with ramp-up of new contracts and market recovery.
Full-year revenue from new contracts projected at BRL 600 million or more.
Double-digit EBITDA margin targeted for the second half of 2026, driven by volume and efficiency.
Structural gains from synergy plan expected to deliver BRL 100 million in 2026 and BRL 180 million annually from 2027.
Stronger market expected for 2027, with sustained demand in North America.
Latest events from Tupy
- Net revenue dropped 9% and restructuring led to a R$ 655 million net loss in 2025.TUPY3
Q4 202530 Apr 2026 - Record EBITDA and cash flow offset lower revenue; new contracts and bioplants drive growth.TUPY3
Q2 20242 Feb 2026 - Record cash flow and margin gains offset revenue and net income declines amid weak demand.TUPY3
Q3 202414 Jan 2026 - Record EBITDA and cash flow achieved despite lower sales, with margin gains and strong outlook.TUPY3
Q4 202423 Dec 2025 - Revenue fell 6% and EBITDA margin dropped, but net income rose 33% on financial gains.TUPY3
Q2 202523 Nov 2025 - Revenue down 4% and net loss, but aftermarket and gensets segments showed strong growth.TUPY3
Q1 202520 Nov 2025 - Revenue and EBITDA fell, but record cash flow and new segments support future margin gains.TUPY3
Q3 202513 Nov 2025